Overview

Immunotherapy of the Paraneoplastic Syndromes

Status:
Completed

Trial end date:
2014-05-01

Target enrollment:
0

Participant gender:
All

Summary

We treat a subset of patients with paraneoplastic neurologic disorders, including those with Yo-mediated paraneoplastic cerebellar degeneration (PCD), the Hu syndrome, which is most commonly associated with small cell lung cancer (SCLC) - paraneoplastic subacute sensory neuropathy, encephalomyelitis, limbic encephalopathy, autonomic neuropathy - and the Ri Syndrome (a.k.a. Paraneoplastic Opsoclonus-Myoclonus Ataxia), as well as those patients suspected to have a paraneoplastic neurologic disorder but in whom a characteristic antibody has not yet been identified. Our treatment protocol consists of immune suppression therapy using tacrolimus (FK506), a potent inhibitor of lymphocyte proliferation that is commonly used to prevent organ transplant rejection.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Rockefeller University

Treatments:

Tacrolimus

Criteria

Inclusion Criteria:

- Patients diagnosed with Paraneoplastic Disorder

Exclusion Criteria:

- Metastasis (spread) of cancer to brain, History of additional active malignancy other
than non-melanoma skin cancer, History of Hepatitis B, Hepatitis C, HIV or Syphilis.